Compare Bristol-Myers Squibb Co (BMY) vs Vanguard Total Bond Market Index Fund ETF (BND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Vanguard Total Bond Market Index Fund ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.41 (market cap $129.94B), while Vanguard Total Bond Market Index Fund ETF trades at $72.3. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Vanguard Total Bond Market Index Fund ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Vanguard Total Bond Market Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BMY | BND | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | — |
52-Week High | $65.89 | $75.17 |
52-Week Low | $42.60 | $72.15 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Vanguard Total Bond Market Index Fund ETF
This index measures the performance of a wide spectrum of public, investment-grade, taxable, fixed income securities in the US, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities-all with maturities of more than 1 year. All of the fund's investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the index.
Read more on BND →
